BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tabirafusp alfa readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tabirafusp alfa\, from ClinicalTrials.gov
  estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06996080-5235@assetmemo.bio
DTSTAMP:20261121T004101Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Tabirafusp alfa: Phase 3 readout est. (NCT06996080)
DESCRIPTION:Tabirafusp alfa\, phase 3.\nStudy: A Phase 3 Study to Evaluate 
 the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macul
 ar Edema Secondary to Inflammation (MESI) - PINNACLE\nEstimated primary co
 mpletion: February 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/tabirafusp-alfa#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06996080
URL:https://assetmemo.bio/drug/tabirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06990399-5235@assetmemo.bio
DTSTAMP:20261121T004101Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Tabirafusp alfa: Phase 3 readout est. (NCT06990399)
DESCRIPTION:Tabirafusp alfa\, phase 3.\nStudy: A Phase 3 Study to Evaluate 
 the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macul
 ar Edema Secondary to Inflammation (MESI) - PEAK\nEstimated primary comple
 tion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tab
 irafusp-alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06990399
URL:https://assetmemo.bio/drug/tabirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
